Biomind Labs Inc

Research Biomind Labs Inc (BMND) on Bullrun: market cap CAD 54.30M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is CAD 54.30M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0-USD 850.41K-USD 67.55Kn/an/aUSD 36USD 728.48K-USD 1.74M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-24CAD 54.30Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 CAD.

About Biomind Labs Inc

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine sublingual formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's disease;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Biomind Labs Inc's market cap?

Biomind Labs Inc's market capitalization is CAD 54.30M.

What does Biomind Labs Inc do?

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions.